BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 21192178)

  • 1. Risk of cervical precancer and cancer in women aged 30 years and older with an HPV-negative low-grade squamous intraepithelial lesion screening result.
    Littell RD; Kinney W; Fetterman B; Cox JT; Shaber R; Poitras N; Lorey T; Castle PE
    J Low Genit Tract Dis; 2011 Jan; 15(1):54-9. PubMed ID: 21192178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or less.
    Katki HA; Gage JC; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Kinney WK
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S69-77. PubMed ID: 23519308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lessons from practice: risk of CIN 3 or cancer associated with an LSIL or HPV-positive ASC-US screening result in women aged 21 to 24.
    Moore G; Fetterman B; Cox JT; Poitras N; Lorey T; Kinney W; Castle PE
    J Low Genit Tract Dis; 2010 Apr; 14(2):97-102. PubMed ID: 20354416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance.
    Safaeian M; Solomon D; Wacholder S; Schiffman M; Castle P
    Obstet Gynecol; 2007 Jun; 109(6):1325-31. PubMed ID: 17540804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis of Cervical Precancers by Endocervical Curettage at Colposcopy of Women With Abnormal Cervical Cytology.
    Liu AH; Walker J; Gage JC; Gold MA; Zuna R; Dunn ST; Schiffman M; Wentzensen N
    Obstet Gynecol; 2017 Dec; 130(6):1218-1225. PubMed ID: 29112672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Similar Risk Patterns After Cervical Screening in Two Large U.S. Populations: Implications for Clinical Guidelines.
    Gage JC; Hunt WC; Schiffman M; Katki HA; Cheung LA; Myers O; Cuzick J; Wentzensen N; Kinney W; Castle PE; Wheeler CM;
    Obstet Gynecol; 2016 Dec; 128(6):1248-1257. PubMed ID: 27824767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive.
    Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S56-63. PubMed ID: 23519306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening properties of human papillomavirus testing for predicting cervical intraepithelial neoplasia in atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesion smears: a prospective study.
    Dane C; Batmaz G; Dane B; Cetin A
    Ann Diagn Pathol; 2009 Apr; 13(2):73-7. PubMed ID: 19302953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Follow-up outcomes in a large cohort of patients with HPV-negative LSIL cervical screening test results.
    Barron S; Austin RM; Li Z; Zhao C
    Am J Clin Pathol; 2015 Apr; 143(4):485-91. PubMed ID: 25779999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reflex Human Papillomavirus Test Results as an Option for the Management of Korean Women With Atypical Squamous Cells Cannot Exclude High-Grade Squamous Intraepithelial Lesion.
    Ryu KJ; Lee S; Min KJ; Kim JW; Hong JH; Song JY; Lee JK; Lee NW
    Oncologist; 2015 Jun; 20(6):635-9. PubMed ID: 25964305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytology versus HPV testing for cervical cancer screening in the general population.
    Koliopoulos G; Nyaga VN; Santesso N; Bryant A; Martin-Hirsch PP; Mustafa RA; Schünemann H; Paraskevaidis E; Arbyn M
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD008587. PubMed ID: 28796882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Follow-up with histopathology and HPV testing on LSIL cytology in China's largest academic woman's hospital.
    Tao X; Zhang H; Zhang H; Xiao J; Li J; Zhou X; Wang L; Zhao C
    Cancer Cytopathol; 2019 Apr; 127(4):258-266. PubMed ID: 30892831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five-year risks of CIN 2+ and CIN 3+ among women with HPV-positive and HPV-negative LSIL Pap results.
    Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S43-9. PubMed ID: 23519304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three-year risk of high-grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co-screening.
    Guo M; Khanna A; Wang J; Dawlett MA; Kologinczak TL; Lyons GR; Bassett RL; Sneige N; Gong Y; Bevers TB
    Cancer Cytopathol; 2017 Aug; 125(8):644-651. PubMed ID: 28498639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy.
    Cox JT; Schiffman M; Solomon D;
    Am J Obstet Gynecol; 2003 Jun; 188(6):1406-12. PubMed ID: 12824970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-risk human papillomavirus detection in women with low-grade squamous intraepithelial lesions or higher-grade cytology using the Cervista HPV HR test.
    Gold MA; Thomas MA; Huh WK; Sarto GE; Day SP
    J Low Genit Tract Dis; 2013 Jan; 17(1):51-7. PubMed ID: 22885641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management.
    Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S78-84. PubMed ID: 23519309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening Guidelines.
    Demarco M; Lorey TS; Fetterman B; Cheung LC; Guido RS; Wentzensen N; Kinney WK; Poitras NE; Befano B; Castle PE; Schiffman M
    J Low Genit Tract Dis; 2017 Oct; 21(4):261-267. PubMed ID: 28953116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of cervical precancer and cancer among HIV-infected women with normal cervical cytology and no evidence of oncogenic HPV infection.
    Keller MJ; Burk RD; Xie X; Anastos K; Massad LS; Minkoff H; Xue X; D'Souza G; Watts DH; Levine AM; Castle PE; Colie C; Palefsky JM; Strickler HD
    JAMA; 2012 Jul; 308(4):362-9. PubMed ID: 22820789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.